Instil Bio, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023. The supplied filing text is marked “DRAFT - DO NOT DISTRIBUTE”; investors should verify the final filed version.
Business context
Instil Bio is a clinical-stage biopharmaceutical company developing autologous tumor-infiltrating lymphocyte (TIL) therapies. It has no approved products and has not generated product-sales revenue. Following restructuring, it discontinued ITIL-168 and prioritized its CoStAR platform, including ITIL-306. Clinical manufacturing and trial operations for ITIL-306 were transitioned to the United Kingdom.
Financial results and liquidity
| Metric | Q3 2023 / September 30, 2023 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $8.5 million | $39.7 million in Q3 2022 |
| General and administrative expense | $11.9 million | $17.0 million in Q3 2022 |
| Restructuring and impairment charges | $46.3 million | None in Q3 2022 |
| Net loss | $67.4 million; $0.52 per share | $56.2 million; $0.43 per share in Q3 2022 |
| Nine-month net loss | $143.2 million; $1.10 per share | $169.3 million; $1.31 per share in 2022 |
| Cash, cash equivalents, restricted cash and marketable securities | $184.5 million | $260.9 million at December 31, 2022 |
| Loan principal outstanding | $82.8 million | $72.4 million net carrying amount at December 31, 2022 |
| Total liabilities / stockholders’ equity | $106.2 million / $234.0 million | $118.5 million / $363.6 million at December 31, 2022 |
For the first nine months of 2023, operating cash use was $68.6 million, investing activities provided $27.2 million, and financing activities provided $8.1 million. Cash, cash equivalents and restricted cash decreased by $33.4 million. The company reported an accumulated deficit of $568.1 million. Profit margins are not meaningful because the company has no product revenue.
Material changes and unusual items
- Q3 R&D expense fell 79% year over year, mainly reflecting workforce reductions, discontinued ITIL-168 activities and lower facilities costs. Nine-month R&D expense declined to $37.6 million from $120.3 million.
- Q3 operating expenses increased to $66.7 million from $56.6 million, primarily because of $46.3 million of restructuring and impairment charges. The nine-month charge was $71.8 million, including $41.5 million for buildings and construction work in progress, $16.2 million for assets held for sale and $7.7 million for right-of-use assets.
- The Tarzana facility was substantially complete but awaiting a final certificate of occupancy. The company is evaluating a sale or lease of the site and subleases of other facilities. Assets held for sale were $1.6 million at quarter-end.
- The variable-rate construction loan is secured by the Tarzana property, bears interest at one-month SOFR plus 5.25%, and matures in July 2025, with an extension option to July 2027. The company reported compliance with its covenants at September 30, 2023, including a $85 million minimum net-worth and liquid-assets requirement.
Outlook, risks and contingencies
- Management believes available cash, cash equivalents, restricted cash and marketable securities will fund operating expenses and capital requirements beyond 2026. This estimate depends on assumptions that may not hold; management says capital could be used sooner than expected.
- Management expects near-term R&D and G&A expense reductions, followed by higher R&D spending as enrollment and progress in the ITIL-306-202 trial require resources. It estimates up to $2.5 million of additional restructuring charges, with material charges expected before year-end 2023 and retention bonuses paid by the end of 2024.
- Key risks include clinical and regulatory uncertainty, patient enrollment, complex cell-therapy manufacturing, prior manufacturing failures and contamination, dependence on the UK operation, competition, and the possibility that facility sales or subleases do not occur on favorable terms or at all. Additional financing may be needed; it could dilute shareholders or impose restrictive terms.
- A former supplier filed a complaint seeking approximately $1.94 million in contract and conversion damages related to a cancelled contract. The company states it does not expect resolution of legal matters to materially adversely affect its financial position, results or cash flows.
- Nasdaq had granted an additional 180-day compliance period after the company failed the minimum bid-price requirement; failure to regain compliance could result in delisting. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the final filed 10-Q and whether any information differs from this draft text.
- Track cash and marketable securities, operating cash burn, and management’s beyond-2026 runway assumptions.
- Monitor ITIL-306-202 trial progress, enrollment, manufacturing success and any regulatory updates.
- Verify the status and economics of a potential Tarzana sale or lease, other facility subleases, and any further impairment charges.
- Review construction-loan covenant compliance, interest-rate exposure and repayment or extension plans.
- Follow the supplier lawsuit and Nasdaq bid-price compliance status.